Skip to main content
SpringerLink
Log in

Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy

  • SHORT REPORTS
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Several previous reports suggest that thrombospondin (TSP-1) may be a mediator of the antiangiogenic effects of low-dose metronomic cyclophosphamide-based chemotherapy (MC). We conducted a randomized phase II trial evaluating megestrol acetate (n = 44) versus MC (n = 44) in patients having exhausted all standard treatments. We measured the TSP-1 levels at baseline and D15. We did not observe significant differences in TSP-1 at baseline in the two arms (p = 0.07). TSP-1 levels decreased in patients receiving metronomic cyclophosphamide (from 16.6 ± 7.2 µg/ml to 12.8 ± 7.4 µg/ml; p = 0.057). The TSP-1 level was stable in patients receiving megestrol acetate. Nevertheless, the TSP-1 level driven by MC did not correlate to clinical benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kerbel RS, Klement G, Prichard KI, Kamen B (2002) Continuous low dose antiangiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 13:12–15

    Article  PubMed  CAS  Google Scholar 

  2. Buckstein R, Kerbel RS, Shaked Y, Noyar R, Foden C, Turner R et al (2006) High-dose celecoxib and metronomic “low dose” cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin’s lymphoma. Clin Cancer Res 12:5190–5198

    Article  PubMed  CAS  Google Scholar 

  3. Bocci G, Francia G, Man S, Lanler S, Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100:1297–1222

    Article  Google Scholar 

  4. Damber JE, Vallbo C, Albertsson P, Lennernäs B, Norrby K (2006) The antitumor effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 58:354–360

    Article  PubMed  CAS  Google Scholar 

  5. Penel N, Clisant S, Dansin E, Desauw C, Dégardin M, Mortier L et al (2010) Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. Br J Cancer 102:1207–1212

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Oscar Lambret, 3, rue F Combemale, 59020, Lille, France

    Amélie Lansiaux, Sophie Salingue, Amélie Dewitte, Stéphanie Clisant & Nicolas Penel

  2. Université Lille Nord de France, Faculté de Médecine de Lille, INSERM U-837, Institut de Recherche sur le Cancer de Lille, Lille, France

    Amélie Lansiaux

  3. Equipe d’Accueil 2694: Santé Publique, Epidémiologie et modélisation des maladies chroniques, Lille, France

    Nicolas Penel

Authors
  1. Amélie Lansiaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Salingue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amélie Dewitte
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stéphanie Clisant
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicolas Penel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolas Penel.

Additional information

Supported by GEFUC-Lille (Groupement des Entreprises Françaises dans la Lutte contre le Cancer)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lansiaux, A., Salingue, S., Dewitte, A. et al. Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy. Invest New Drugs 30, 403–404 (2012). https://doi.org/10.1007/s10637-010-9443-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-010-9443-1

Keywords

Search

Navigation